News & Updates
Filter by Specialty:
Gut dysbiosis evident in patients with prodromal PD and their first-degree relatives
A cross-sectional study from the Chinese University of Hong Kong suggests that Parkinson’s disease (PD)–like gut dysbiosis occurs at preclinical prodromal stages of PD, in patients with video-polysomnography (v-PSG)–confirmed REM sleep behavior disorder (RBD) and even in their younger first-degree relatives (RBD-FDR).
Gut dysbiosis evident in patients with prodromal PD and their first-degree relatives
10 May 2023Preconception HBV history linked to congenital heart disease risk in offspring
Children born to mothers who had contracted hepatitis B virus (HBV) infection before pregnancy appear to be at increased risk of congenital heart diseases (CHDs), as reported in a study.
Preconception HBV history linked to congenital heart disease risk in offspring
04 May 2023Older IBD patients at disadvantage for medications, surgery
Older patients with inflammatory bowel disease (IBD) are less likely to be initiated on medications and are often scheduled for surgeries, a study has found.
Older IBD patients at disadvantage for medications, surgery
29 Apr 2023Elective sigmoid resection wards off recurrent diverticulitis, enhance quality of life
For patients with recurrent, complicated, or persistent painful diverticulitis, elective sigmoid resection appears to prevent recurrence as well as improve quality of life (QOL) within 2 years as compared with conservative treatment, according to the results of an open-label trial.
Elective sigmoid resection wards off recurrent diverticulitis, enhance quality of life
26 Apr 2023Patients at risk for BE worried over EAC but rarely undergoes screening: study
Patients who are prone to Barrett’s esophagus (BE), specifically those belonging to racial and ethnic minorities, express concern about developing esophageal adenocarcinoma (EAC), reveals a study. However, they seldom go through screening and lack awareness of screening recommendations.
Patients at risk for BE worried over EAC but rarely undergoes screening: study
25 Apr 2023Vonoprazan-amoxicillin combo on par with B-quadruple therapy for H. pylori infection
Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.